These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31161482)

  • 1. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
    Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
    AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
    Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
    Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
    [No Abstract]   [Full Text] [Related]  

  • 4. A new method for identification of outliers in immunogenicity assay cut point data.
    Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
    J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size consideration for immunoassay screening cut-point determination.
    Zhang J; Zhang L; Yang H
    J Biopharm Stat; 2014; 24(3):535-45. PubMed ID: 24697778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmatory cut point has limited ability to make accurate classifications in immunogenicity assays.
    Kubiak RJ; Arends RH; Lee N; Liang M; Zhang J; Roskos LK
    Bioanalysis; 2020 Feb; 12(4):245-256. PubMed ID: 32090586
    [No Abstract]   [Full Text] [Related]  

  • 8. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance.
    Song S; Yang L; Trepicchio WL; Wyant T
    J Immunol Res; 2016; 2016():3072586. PubMed ID: 27340678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.
    Weeraratne DK; Lofgren J; Dinnogen S; Swanson SJ; Zhong ZD
    J Immunol Methods; 2013 Oct; 396(1-2):44-55. PubMed ID: 23933325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Method validation of a bridging immunoassay in combination with acid-dissociation and bead treatment for detection of anti-drug antibody.
    Du J; Yang Y; Zhu L; Wang S; Yu C; Liu C; Long C; Chen B; Xu G; Zou L; Wang L
    Heliyon; 2023 Mar; 9(3):e13999. PubMed ID: 36915535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Storage Conditions of Conjugated Reagents Can Impact Results of Immunogenicity Assays.
    Kubiak RJ; Lee N; Zhu Y; Franch WR; Levitskaya SV; Krishnan SR; Abraham V; Akufongwe PF; Larkin CJ; White WI
    J Immunol Res; 2016; 2016():1485615. PubMed ID: 27478855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan.
    Ishii-Watabe A; Shibata H; Nishimura K; Hosogi J; Aoyama M; Nishimiya K; Saito Y
    Bioanalysis; 2018 Jan; 10(2):95-105. PubMed ID: 29243491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Memory B Activity Against a Therapeutic Protein in Treatment-Naïve Subjects.
    Liao K; Derbyshire S; Wang KF; Caucci C; Tang S; Holland C; Loercher A; Gunn GR
    AAPS J; 2018 Mar; 20(3):51. PubMed ID: 29549534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays.
    Jaki T; Lawo JP; Wolfsegger MJ; Singer J; Allacher P; Horling F
    J Pharm Biomed Anal; 2011 Jul; 55(5):1148-56. PubMed ID: 21561734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bridging immunogenicity assay for anti-cabiralizumab antibodies: overcoming the low assay cut point and drug tolerance challenges.
    Yuan L; Gleason CR; Stocker D; Li L; Shen JX; Ji QC
    Bioanalysis; 2021 Mar; 13(5):395-407. PubMed ID: 33661021
    [No Abstract]   [Full Text] [Related]  

  • 19. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity assay cut point determination using nonparametric tolerance limit.
    Zhang J; Li W; Roskos LK; Yang H
    J Immunol Methods; 2017 Mar; 442():29-34. PubMed ID: 28063769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.